Operative management of primary epithelial ovarian cancer

Current Oncology Reports

Volumn 9, Issue 6, 2007, Pages 478-484

  Leitao Jr , Mario M ^b   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ACCURACY; ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PATIENT SELECTION; PELVIS LYMPH NODE; PERITONEAL CATHETER; PREOPERATIVE EVALUATION; PROGNOSIS; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR LOCALIZATION;

CLINICAL TRIALS AS TOPIC; EPITHELIAL CELLS; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 36048952659     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0067-3     Document Type: Review

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
3. Heintz AP, Odicino F, Maisonneuve P, et al.: Carcinoma of the ovary. J Epidemiol Biostat 2001, 6:107-138.
4. Hoskins WJ: Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993, 71:1534-1540.
5. Tingulstad S, Skjeldestad FE, Hagen B: The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 2003, 102:499-505.
6. Aletti GD, Gostout BS, Podratz KC, Cliby WA: Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 2006, 100:33-37.
7. Earle CC, Schrag D, Neville BA, et al.: Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006, 98:172-180.
8. Schilder JM, Thompson AM, DePriest PD, et al.: Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002, 87:1-7.
9. Benjamin I, Morgan MA, Rubin SC: Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 1999, 72:288-291.
10. Young RC, Decker DG, Wharton JT, et al.: Staging laparotomy in early ovarian cancer. JAMA 1983, 250:3072-3076.
11. Le T, Adolph A, Krepart GV, et al.: The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol 2002, 85:351-355.
12. Petru E, Lahousen M, Tamussino K, et al.: Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol 1994, 170:656-662.
13. Cass I, Li AJ, Runowicz CD, et al.: Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001, 80:56-61.
14. Tsumura N, Sakuragi N, Hareyama H, et al.: Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer (Pred Oncol) 1998, 79:526-530.
15. Trimbos JB, Vergote I, Bolis G, et al.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer - adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 2003, 95:113-125.
16. Arango HA, Hoffman MS, Riberts WS, et al.: Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. Obstet Gynecol 2000, 95:553-556.
17. Eltabbakh GH: Intraoperative clinical evaluation of lymph nodes in women with gynecologic cancer. Am J Obstet Gynecol 2001, 184:1177-1181.
18. Chi DS, Abu-Rustum NR, Sonoda Y, et al.: The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol 2005, 192:1614-1619.
19. Juretzka MM, Abu-Rustum NR, Sonoda Y, et al.: The impact of video-assisted thoracic surgery (VATS) in patients with suspected advanced ovarian malignancies and pleural effusions. Gynecol Oncol 2007, 104:670-674.
20. Norton L: Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001, 6(Suppl 3):30-35.
21. Goldie JH, Coldman JA: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727-1733.
22. Boente MP, Chi DS, Hoskins WJ: The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998, 25:326-334.
23. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975, 42:101-104.
24. Hoskins WJ, McGuire WP, Brady MF, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170:974-980.
25. Chi DS, Eisenhauer EL, Lang J, et al.: What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006, 103:559-564.
26. Crawford SC, Vasey PA, Paul J, et al.: Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 2005, 23:8802-8811.
27. Covens AL: A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000, 78:269-274.
28. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
29. Chi DS, Franklin CC, Levine DA, et al.: Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004, 94:650-654.
30. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al.: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 2006, 103:1083-1090.
31. Aletti GD, Dowdy SC, Gostout BS, et al.: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006, 107:77-85.
32. Chi DS, Eisenhauer EL, Sonoda Y, et al.: Improved overall survival for patients with advanced ovarian, tubal, and primary peritoneal carcinoma as a result of a change in surgical approach: a follow-up study. J Clin Oncol 2007, 25:281S.
33. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
34. Leitao MM Jr, Chi DS: Cytoreductive surgery for ovarian cancer. Postgrad Obstet Gynecol 2004, 24:1-8.
35. Bristow RE, Moritz FJ, Lagasse LE, et al.: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999, 72:278-287.
36. Aletti GD, Dowdy SC, Podratz KC, Cliby WA: Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol 2007, 105:84-89.
37. Vergote I, Van Gorp T, Amant F, et al.: Neoadjuvant chemotherapy for ovarian cancer. Oncology 2005, 19:1615-1622.
38. Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006, 103:1070-1076.
39. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
40. van der Burg MEL, van Lent M, Buyse M, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995, 332:629-634.
41. Rose PG, Nerenstone S, Brady MF, et al.: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004, 351:2489-2497.